Preventing relapse in people with HIV and alcohol use issues

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This pilot trial aims to evaluate the effectiveness and feasibility of a brief counseling intervention designed for individuals with HIV who have experienced a relapse in alcohol use after a period of abstinence. Participants will receive either a person-delivered or a computer-delivered relapse prevention intervention, which will be compared to standard alcohol counseling provided at the HIV clinic. The study will also assess how acceptable and feasible these interventions are for implementation in a clinical setting.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Confirmed diagnosis of HIV
* Aged 18 years or older
* Must be enrolled in clinical care at Johns Hopkins HIV Clinic.

In addition, meet the following alcohol use criteria:

1. lifetime alcohol use disorder
2. patient reported outcomes (PRO) assessment collected by the Center for AIDS Research (CFAR) Network of Clinical Systems as part of usual clinical care that show in the last 3 years: periods of no or lower risk drinking (e.g. women/men who are drinking \<11/22 drinks per week) and periods of lapse to higher levels of drinking (=\>11/22 drinks per week for women/men)
3. current PRO showing alcohol abstinence or alcohol use at \<11/22 drinks per week for women/men.

Exclusion Criteria:

* Acutely suicidal, homicidal, psychotic or otherwise unable to provide informed consent
* Non-English speaking because interventions are currently available in English only

Where it's running

• Johns Hopkins School of Medicine
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Heidi Hutton, PhD — Johns Hopkins School of Medicine
• Study coordinator: Heidi Hutton, PhD
• Email: hhutton@jhmi.edu
• Phone: 14104586715

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Emotional Reactivity in Severe Alcohol Use Disorder and Depression Using Eye-Tracking and Physiological Measures

  This study tests how people with severe alcohol use disorder, major depressive disorder, both conditions, or neither, recognize and react to emotions using eye-tracking and physiological data.

  Recruiting Université Catholique de Louvain · Brussels, Belgium · NCT07925281

• Thiamine to reduce brain injury in adults with alcohol use disorder

  This trial tests whether thiamine can help protect the brain in adults with moderate to severe alcohol use disorder who drink daily.

  Recruiting Phase 2 Institut National de la Santé Et de la Recherche Médicale, France · Paris, Île-de-France Region · NCT07844720

• Project SHIELD 2.0: Police Education to Support Public Health in Kentucky

  Aimed at police in Kentucky, this program tests whether SHIELD training given to officers, with health workers helping deliver it, can reduce drug-related arrests and steer people who use drugs toward MOUD and other health services.

  Recruiting Johns Hopkins Bloomberg School of Public Health · Lexington, Kentucky · NCT07804121

• New ways to diagnose lymphoma and multicentric Castleman disease in people living with HIV

  This study tests a quick, point-of-care nucleic acid test to help diagnose lymphoma and multicentric Castleman disease in people living with HIV in sub-Saharan Africa.

  Recruiting Indiana University · Lilongwe · NCT07793006

• Bridge to Belonging: A Peer‑Led Program to Reduce Loneliness and Depression in older gay and bisexual men with HIV

  This program tests a peer-delivered, manualized approach to help men aged 50+ with HIV connect to LGBTQ+-affirming elder services to see if it reduces loneliness and depressive symptoms.

  Recruiting Fenway Community Health · Boston, Massachusetts · NCT07762066

• HIV vaccine test in healthy adults using CH505 nanoparticles and mRNA boosters

  This early-stage study will test the safety and immune responses of CH505 vaccine regimens in healthy adults to see if they can trigger HIV-specific immune protection.

  Recruiting at 2 sites Phase 1 National Institute of Allergy and Infectious Diseases (NIAID) · San Francisco, California and 7 other locations · NCT07757802

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.